HLA-B*5701 ASSOCIATED HCP5 RS2395029 GENOTYPING FOR ABACAVIR HYPERSENSITIVITY, EDTA BLOOD

image not found

NABL Cap Accredited     
This genetic test detects the presence of HLA-B*5701 and associated HCP5 RS2395029 variants that predict hypersensitivity to abacavir, an antiretroviral medication used in HIV treatment. Identifying these genetic markers helps prevent potentially severe allergic reactions before starting therapy. The test is particularly useful for personalized medicine and safe HIV management. Metropolis Healthcare performs this test using advanced genotyping techniques to ensure precise and reliable results from EDTA blood samples

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 3,390.00

Sample Type: EDTA BLOOD

Fasting Not Required


Notes: H0249

Frequently Asked Questions (FAQ's):

What does this HLA-B*5701 genotyping test detect?
It identifies HLA-B*5701 and HCP5 RS2395029 variants linked to abacavir hypersensitivity.

Who should undergo this test?
HIV-positive patients who are candidates for abacavir-containing antiretroviral therapy.

How does Metropolis Healthcare perform this test?
Metropolis Healthcare uses advanced DNA genotyping techniques to detect the presence of relevant genetic variants.

What type of sample is required?
An EDTA-anticoagulated blood sample collected via routine venipuncture.

Is fasting required for this test?
No fasting or special preparation is necessary.

What does a positive result indicate?
It indicates increased risk of hypersensitivity to abacavir, suggesting the need for alternative medication.

Can this test guide treatment decisions?
Yes, it helps clinicians choose safe antiretroviral therapy and prevent severe allergic reactions.

How soon are results available from Metropolis Healthcare?

Results are typically available within 2–3 working days 

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab